Drug Delivery Systems ; Humans ; Neoplasms ; drug therapy ; etiology ; pathology ; Neoplastic Stem Cells ; pathology ; physiology ; Neovascularization, Pathologic

Lung cancer is a highly vascular tumors, over the past ten years, anti-angiogenes is has been proved to be an effective and highly promising combinational treatment. The data of the combination of anti-angiogenesis with chemotherapy, targeted therapy, immunotherapy has been constantly updating. Advanced lung cancer patients, no matter different groups or different stages of the disease, are benefited from anti-angiogenes. In this paper, based on the clinical status and unsolved problems, combined with the latest clinical and translational research data, we reviewed the current anti-angiogenesis treatment of lung cancer.
.
Angiogenesis Inhibitors/therapeutic use* ; Humans ; Immunotherapy ; Lung Neoplasms/pathology* ; Molecular Targeted Therapy ; Neovascularization, Pathologic/drug therapy*

Photodynamic therapy (PDT) involves the induction of endothelial cell death or occlusion of blood vessels. On the basis of this mechanism of action, PDT is used in the treatment of predominant classic choroidal neovascularization (CNV), if the classic component is over 50%, and in myopic CNV. This study describes 2 cases of distinctive, abnormal, large, subretinal new vessels that are thought to have originated from the choroids. Diminishment of the new vessels was observed following treatment with PDT.
Retinal Vessels/drug effects/*pathology ; Retinal Diseases/*drug therapy/pathology ; *Photochemotherapy ; Neovascularization, Pathologic/*drug therapy/pathology ; Middle Aged ; Male ; Humans ; Female ; Angiography

Aged ; Diagnosis, Differential ; Drug Therapy, Combination ; Female ; Humans ; Liver ; blood supply ; pathology ; Multiple Myeloma ; diagnostic imaging ; drug therapy ; pathology ; Neovascularization, Pathologic ; diagnosis ; pathology ; Tomography, X-Ray Computed

OBJECTIVETo investigate the inhibition effect of Salvia chinensis extraction (SJC) on growth of H22 bearing tumor, and to analyze the mechanism about the anti-tumor effect.

METHODWith hepatoma H22 bearing mice, ICR mice were inoculated with H22 cells by subcutaneous injection. On day 2 after inoculation, the ICR mice were randomize into 5 groups, they were the control group, the high, middle, low dosages of SJC, and the positive-control group. Administrated 10 days, the inhibition rate of tumor in the treatment groups were analyzed at 11th day. Meanwhile, Immunostaining with antibodies against CD105 and VEGF were used to investigate the tumor-related angiogenesis. In addition, the effect of SJC on angiogenesis of tumor were investigated on chick embry chorioallantoic membrane (CAM) inoculated H22 cells.

RESULTIn contrast to model group, the inhibition rate of the high, middle, and low dosages of SJC were 26.44% (P < 0.05), 42.28% (P < 0.01) and 32.59% (P < 0.05), respectively, and SJC could significantly reduced the express of VEGF and microvessel density (MVD) (P < 0.01). Injection with 6.25 g x L(-1) doses of SJC could significantly inhibited the angiogenesis of tumor, the inhibition rate of tumor-related angiogenesis was 50.67% (P < 0.01).

CONCLUSIONSJC showed anticancer effect, and maybe it is related to down-regulation VEGF and reducing MVD, then inhibiting the tumor-related angiogenesis.

Animals ; Carcinoma, Hepatocellular ; drug therapy ; metabolism ; pathology ; Cell Line, Tumor ; Male ; Mice ; Mice, Inbred ICR ; Neovascularization, Pathologic ; drug therapy ; metabolism ; pathology ; Plant Extracts ; therapeutic use ; Salvia ; chemistry

Angiogenesis Inhibitors ; pharmacology ; therapeutic use ; Carcinoma, Non-Small-Cell Lung ; blood supply ; pathology ; Humans ; Lung Neoplasms ; blood supply ; pathology ; Neovascularization, Pathologic ; drug therapy ; therapy ; Societies, Medical

Malignant tumor is the common disease that threaten severely to people's health. Formulae of traditional Chinese medicine (FTCM), as the major component of traditional drugs, has played more important role on the prevention and cure to tumor. The Folkman's theory that tumorous growth depends on tumor neovascularization has been confirmed so many years, so to inhibit the tumor angiogenesis, is an important path to treat tumor. The research of FTCM to antagonizing tumor angiogenesis in our country has been started more lately. Since it has been reported some FTCMs can inhibit angiogenesis, and it also exists many problems. The article summarized the correlated research of FTCM to antagonize tumor angiogenesis for the past several years, and according this, analyzed, stated and commented to the problems, countermeasures, development and direction of PTCM to antagonize tumor angiogenesis.
Animals ; Chemistry, Pharmaceutical ; Drugs, Chinese Herbal ; therapeutic use ; Humans ; Medicine, Chinese Traditional ; Neoplasms ; drug therapy ; pathology ; prevention & control ; Neovascularization, Pathologic ; drug therapy ; prevention & control

OBJECTIVETo investigate the inhibitory effects of spironolactone against hepatic sinusoid angiogenesis in rats with hepatic fibrosis.

METHODSTwenty-four male Wistar rats were randomly divided into sham-operated group, bile duct ligation (BDL) group, and BDL+SP group in which the rats received daily spironolactone injection (20 mg/kg) the day after BDL. Four weeks after the operation, the rats were sacrificed for examination of liver histology using Masson staining and the expression of vascular endothelial growth factor A (VEGF-A) mRNA in the liver using real-time quantitative PCR. Immunohistochemistry was used to detect the expression of von Willebrand factor (vWF) in the hepatic tissues.

RESULTSSpironolactone significantly inhibited liver fibrogenesis in rats after BDL (METAVIR liver fibrosis scores 2.84∓0.44 vs 19.73∓3.54, P=0.00). Real-time PCR and immunohistochemistry showed that compared with BDL group, spironolactone treatment significantly inhibited the expression of VEGF-A mRNA (0.71∓0.12 vs 1.75∓0.15, P=0.00) and vWF (1.15∓0.09 vs 3.08∓0.17, P=0.00) in the liver. The expression of VEGF-A mRNA was highly correlated with the expression of vWF (r=0.890, P=0.000).

CONCLUSIONSpironolactone can inhibit hepatic sinusoid angiogenesis in rats with BDL-induced hepatic fibrosis by inhibiting the expression of VEGF-A.

Animals ; Hepatic Veins ; pathology ; Liver Cirrhosis, Experimental ; metabolism ; pathology ; Male ; Neovascularization, Pathologic ; drug therapy ; RNA, Messenger ; genetics ; Rats ; Rats, Wistar ; Spironolactone ; pharmacology ; Vascular Endothelial Growth Factor A ; metabolism

OBJECTIVEThis review aims to summarize the progress of current clinical studies in ocular angiogenesis treated with anti-vascular endothelial growth factor (VEGF) therapy and to discuss the benefits and challenges of the treatment.

DATA SOURCESPubmed, Embase and the Cochrane Library were searched with no limitations of language and year of publication.

STUDY SELECTIONClinical trials and case studies presented at medical conferences and published in peer-reviewed literature in the past decade were reviewed.

RESULTSAnti-VEGF agents have manifested great potential and promising outcomes in treating ocular neovascularization, though some of them are still used as off-label drugs. Intravitreal injection of anti-VEGF agents could be accompanied by devastating ocular or systemic complications, and intimate monitoring in both adult and pediatric population are warranted. Future directions should be focused on carrying out more well-designed large-scale controlled trials, promoting sustained duration of action, developing safer and more efficient generation of anti-VEGF agents.

CONCLUSIONSAnti-VEGF treatment has proved to be beneficial in treating both anterior and posterior neovascular ocular diseases. However, more safer and affordable antiangiogenic agencies and regimens are warranted to be explored.

Antibodies, Monoclonal, Humanized ; therapeutic use ; Aptamers, Nucleotide ; therapeutic use ; Bevacizumab ; Eye ; blood supply ; drug effects ; pathology ; Humans ; Neovascularization, Pathologic ; drug therapy ; Ranibizumab ; Vascular Endothelial Growth Factor A ; antagonists & inhibitors

The contribution of angiogenesis inhibitor TNP-470 to the growth and metastasis of ACHN renal cell carcinoma (RCC) was studied. TNP-470 (40 mg/kg, every two days) was administrated to BABL/c nude mice bearing ACHN RCC. The mice were sacrificed after a treatment duration of 31 days and the weight and volume of subcutaneous tumors as well as foci of lung metastasis were measured. The microvascular density (MVD) of the tumor as well as the PCNA index and apoptotic index of the tumor cells were evaluated immunohistochemically. Result showed that the growth of ACHN RCC was suppressed significantly and none metastasis was observed in TNP-470-treated mice. Compared with the control group, the MVD was decreased markedly (P < 0.01) and the apoptotic index was increased significantly (P < 0.01) in the treated group. The tumor volume was positively correlated to the MVD (r = 0.7144, P < 0.01) and inversely correlated to the apoptotic index (r = -0.8607, P < 0.01), and MVD was conversely correlated to the apoptotic index. It was determined that TNP-470 could effectively inhibit angiogenesis of ACHN RCC, which resulting in ischemia and hypoxia, leading to increased apoptosis, thus obviously suppressing the growth and metastasis of ACHN RCC in nude mice.
Angiogenesis Inhibitors ; pharmacology ; Animals ; Apoptosis ; drug effects ; Carcinoma, Renal Cell ; drug therapy ; pathology ; secondary ; Cell Division ; Cyclohexanes ; Female ; Kidney Neoplasms ; drug therapy ; pathology ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Neoplasm Transplantation ; Neovascularization, Pathologic ; prevention & control ; Random Allocation ; Sesquiterpenes ; pharmacology